News & Events about Ignyta Inc.
Prometheus Biosciences, Inc. (NASDAQ:RXDX Get Rating) CEO Mark C. Mckenna sold 25,000 shares of the stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $118.99, for a total value of $2,974,750.00. Following the transaction, the chief executive officer now ...
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc.(Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of ...
SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX),a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of ...
Thinking about trading options or stock in Prometheus Biosciences, Apple, Chevron, DexCom, or Amazon? Thinking about trading options or stock in Prometheus Biosciences, Apple, Chevron, DexCom, or Amazon? PR Newswire NEW YORK, Dec. 8, 2022 NEW YORK, Dec. 8, 2022 /PRNewswire...
Thinking about buying stock in Prometheus Biosciences, Meta Materials, Eterna Therapeutics, Roivant Sciences, or China Automotive Systems? Thinking about buying stock in Prometheus Biosciences, Meta Materials, Eterna Therapeutics, Roivant Sciences, or China Automotive Systems? PR Newswire NEW YORK...